MarketPulse

drug pipeline

14 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Hepatic Encephalopathy Market Poised for Steady Growth as New Therapies Address Rising Disease Burden

Hepatic encephalopathy market projected to grow 1.2% annually through 2036, reaching $900M in 2025, driven by emerging therapies and increased diagnosis awareness.
GRFSBHCclinical trialsmarket growth
The Motley FoolThe Motley Fool··Selena Maranjian

Eli Lilly's Weight-Loss Dominance and Cancer Pipeline Justify Premium Valuation

Eli Lilly shows 43% revenue growth and 51% EPS growth, backed by weight-loss drug leadership and $7B cancer acquisition. Forward P/E of 40 remains below historical average.
LLYvaluationearnings growth
The Motley FoolThe Motley Fool··Jack Delaney

Small-Cap Biotech vs. Pharma Giants: Navigating Risk and Reward in Healthcare

Small-cap biotech like CTMX offers explosive growth potential but carries significant risk; megacap pharma like JNJ provides stability and dividends with moderate returns.
JNJCTMXstock volatilityportfolio diversification
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Polycythemia Vera Market Poised for Major Expansion as Nine Pharma Giants Rush New Therapies

Polycythemia vera market expected to expand 8.9% CAGR through 2036 from $2B base as nine pharma companies advance novel therapies, with rusfertide entering first.
MRKPTGXIRONTAKIONS+1clinical trialsmarket expansion
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's Decade of Dominance: GLP-1 Boom Masks Rising Competition

$LLY surged 1,100% in ten years via GLP-1 drugs, but 39x P/E ratio and patent risks loom.
PFELLYNVOGLP-1 drugspharmaceutical competition
The Motley FoolThe Motley Fool··Jack Delaney

J&J Beats Earnings but Faces Patent Cliff Reality Check

Johnson & Johnson exceeded Q1 2026 expectations and raised guidance, though stock declined as Stelara patent losses offset strong drug sales.
JNJdividendgeneric competition
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly Surges Past Novo Nordisk to $1T, Dominated GLP-1 Market

Eli Lilly reaches $1 trillion valuation while outperforming Novo Nordisk over three years, driven by superior weight-loss drug efficacy and robust pipeline strength.
LLYNVOclinical trialsmarket valuation
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly Edges Vertex as Superior Growth Pick Amid GLP-1 Boom

Eli Lilly ($LLY) outpaces Vertex ($VERX) as superior growth stock pick with Zepbound dominance in booming weight-loss market and stronger financials at comparable valuations.
LLYVRTXcystic fibrosispharmaceutical growth
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Tonix Pharma to Showcase Commercial Portfolio at BIO-Europe Spring 2026

Tonix Pharmaceuticals CEO to present commercial CNS portfolio at BIO-Europe Spring 2026, showcasing TONMYA® fibromyalgia launch success with 1,500+ prescriptions since November 2025.
TNXPclinical trialsbiotechnology
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Weight-Loss Dominance Faces Pipeline Challengers, But Lead Remains Secure

Eli Lilly dominates weight-loss pharmaceuticals with 45% 2025 revenue growth, maintaining market lead despite competitor advances due to years-long regulatory timelines.
LLYNVORHHBYREGNclinical trialsweight loss drugs
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling Praxis Stock Soars 700% as Major Fund Doubles Down With $266M Bet

Deerfield Management boosts $PRAX stake to $266M as biotech stock surges 685% annually. Company eyes $20B+ pipeline revenue potential with two FDA applications pending.
PRAXFDA approvalbiotech
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Regeneron's Pipeline Depth and Dupixent Dominance Set Stage for Decade of Growth

Regeneron's Dupixent dominance and deep pipeline across weight management, oncology, and rare diseases position the company for sustained growth through the mid-2030s.
REGNbiotechpatent cliff
The Motley FoolThe Motley Fool··Matthew Benjamin

Eli Lilly Positions Itself as Pharma Leader Through GLP-1 Dominance and Strategic M&A

Eli Lilly strengthens market position through GLP-1 dominance and strategic acquisitions like Orna Therapeutics, diversifying growth beyond patent cliff risks.
PFELLYacquisitionsgene therapy
The Motley FoolThe Motley Fool··Matthew Benjamin

Eli Lilly Acquires Orna Therapeutics for $2.4B to Expand Gene Therapy Pipeline

Eli Lilly acquires Orna Therapeutics for $2.4B to gain circular RNA gene therapy technology and autoimmune disease candidates, strengthening its pipeline.
MRKLLYacquisitionclinical trials